MedTrace Logo

ROSE-Longitudinal Assessment With Neuroimaging

NCT05089331 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-07-04

No results posted yet for this study

Summary

The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date.

Conditions

  • Intracerebral Hemorrhage

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Maryland, Baltimore

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • Baptist Health, Louisville

    collaborator OTHER

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Daniel Woo, MD, MS · State University of New York at Buffalo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2026-03-01
Completion
2026-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089331 on ClinicalTrials.gov